Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Bionano Genomics, Inc. (BNGO) had Revenue of $6.46M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$6.46M
Net Income	$-3.10M
Cost of Goods Sold	$3.52M
Gross Profit	$2.94M
Operating Expenses	$14.92M
Operating Income	$-8.46M
Non-Operating Income/Expense	$5.37M
Pre-Tax Income	$-3.10M
Normalized Pre-Tax Income	$-3.10M
Income after Taxes	$-3.10M
Income from Continuous Operations	$-3.10M
Consolidated Net Income/Loss	$-3.10M
Normalized Income after Taxes	$-3.10M
EBIT	$-8.46M
EBITDA	$-6.22M
Weighted-Average Shares Outstanding (Basic)	2.69M
Weighted-Average Shares Outstanding (Diluted)	2.69M
Earnings per Share (EPS) (Basic)	$-1.15
Earnings per Share (EPS) (Diluted)	$-1.15
Balance Sheet Financials
Current Assets	$44.93M
Property, Plant, and Equipment	$18.34M
Long-Term Assets	$33.48M
Total Assets	$78.41M
Current Liabilities	$26.41M
Long-Term Debt	$3.53M
Long-Term Liabilities	$3.82M
Total Liabilities	$30.23M
Common Equity	$48.19M
Tangible Shareholders Equity	$39.82M
Shareholders Equity	$48.19M
Common Shares Outstanding	3.10M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-2.76M
Cash Flow from Investing Activities	$-14.07M
Cash Flow from Financial Activities	$10.89M
Beginning Cash	$9.57M
End Cash	$3.62M
Increase/Decrease in Cash	$-5.95M
Stock-Based Compensation	$1.59M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.70
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.07
Debt to Equity Ratio	0.35
Gross Margin	45.50%
Operating Margin	-131.10%
EBIT Margin	-131.10%
EBITDA Margin	--
Pre-Tax Profit Margin	-47.93%
Profit Margin	-48.04%
Free Cash Flow	$-2.76M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.37
Receiveable Turnover	1.93
Days Sales in Receivables	46.75
Return on Equity	-6.44%
Return on Tangible Equity	-7.79%
Return on Assets	-3.96%
Return on Investments	-6.00%
Book Value Per Share	$15.54
Free Cash Flow per Share	$-1.03
Operating Cash Flow per Share	$-1.03

Data from Zacks Investment Research, Inc.